Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 10Neoplasms 8Fallopian Tube Neoplasms 8Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Brain Neoplasms 4Astrocytoma 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Gliosarcoma 3Glioblastoma 3Colonic Neoplasms 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2

Interventions

veliparib 1tipifarnib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Neoplasm × veliparib × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡